Trial Profile
A Phase I, multicenter, Open-label, Dose-Escalation and Expansion Study to evaluate the safety and tolerability of Iodine 131 labeled acitretide injection which is CEA targeting monoclonal antibody in the treatment of advanced malignant solid tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Iodine-131-actuximab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 28 Nov 2017 New trial record